RXRX241115P6000
- 0.20
- -0.03-13.04%
Recursion Pharmaceuticals Newsroom
KeyBanc Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $12
Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Maintains Target Price $10
Needham Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Cuts Target Price to $11
A Quick Look at Today's Ratings for Recursion Pharmaceuticals(RXRX.US), With a Forecast Between $8 to $14
Recursion Pharmaceuticals Maintains Buy Rating Amidst Modest Study Results and Strong Financial Position
Hold Rating on Recursion Pharmaceuticals Amidst Lukewarm Phase 2 Results and AI Platform Validation Concerns
Recursion Pharmaceuticals Analyst Ratings
Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $10
Recursion Pharmaceuticals (RXRX) Gets a Hold From Morgan Stanley
Analysts Offer Insights on Healthcare Companies: Insulet (PODD), Carisma Therapeutics (CARM) and Recursion Pharmaceuticals (RXRX)
Strategic Merger and Financial Prospects Affirm Buy Rating for Recursion Pharmaceuticals
Recursion Pharmaceuticals Analyst Ratings
Needham Maintains Buy on Recursion Pharmaceuticals, Lowers Price Target to $16
Recursion Pharmaceuticals (RXRX) Receives a Hold From TD Cowen
KeyBanc Cuts Price Target on Recursion Pharmaceuticals to $12 From $16, Maintains Overweight Rating
Recursion Pharmaceuticals Analyst Ratings
Keybanc Maintains Overweight on Recursion Pharmaceuticals, Lowers Price Target to $12
Jefferies Initiates Recursion Pharmaceuticals at Hold With $8 Price Target
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $17 Price Target
Recursion Pharmaceuticals Analyst Ratings